----
Current ValuationThe current P/E ratio is 43.65, within the reasonable range, cheaper than 59.39% of the time in the past 1 years, and the industry ranks 48/255, the industry Median -1.04.
43.65xP/E
$21.51Stock price
$0.49Earnings per share
43.65xP/E
Stock price$21.51Earnings per share$0.49
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- 52.05x
- Typical range
- 37.38x–667.09x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
03876114152
The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
| Name/Symbol | |||
|---|---|---|---|
JNJUSJohnson & Johnson | 40.86x | 38.06% | $657.68B |
NVSUSNOVARTIS AG | 30.47x | 0.08% | $305.62B |
PFEUSPfizer | 40.14x | 18.73% | $173.95B |
RDYUSDr Reddys Laboratories | 39.47x | 12.08% | $11.80B |
AMRXUSAmneal Pharmaceuticals | 43.65x | 121.20% | $6.87B |
IBOUSImpact BioMedical | 41.04x | -- | $32.47M |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
